{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1+Clinical+Trial&page=23",
    "query": {
      "condition": "Phase 1 Clinical Trial",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 9283,
    "total_pages": 929,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1+Clinical+Trial&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1+Clinical+Trial&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T08:57:37.125Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01575925",
      "title": "Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Renal Impairment"
      ],
      "interventions": [
        {
          "name": "4 mg Oral POM + 40 mg Oral DEX",
          "type": "DRUG"
        },
        {
          "name": "2 mg Oral POM + 40 mg Oral DEX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2012-06-01",
      "completion_date": "2018-08-07",
      "has_results": false,
      "last_update_posted_date": "2022-11-04",
      "last_synced_at": "2026-11-19T08:57:37.125Z",
      "location_count": 7,
      "location_summary": "Denver, Colorado • Atlanta, Georgia • Harvey, Illinois + 4 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Harvey",
          "state": "Illinois"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01575925"
    },
    {
      "nct_id": "NCT00017940",
      "title": "Gene Therapy for Alzheimer's Disease Clinical Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Human Nerve Growth Factor",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "The Shiley Family Trust",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 8,
      "start_date": null,
      "completion_date": "2003-11",
      "has_results": false,
      "last_update_posted_date": "2009-12-11",
      "last_synced_at": "2026-11-19T08:57:37.125Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00017940"
    },
    {
      "nct_id": "NCT02014649",
      "title": "Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "20 mg laninamivir octanoate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "40 mg laninamivir octanoate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biota Scientific Management Pty Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 15,
      "start_date": "2013-11",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2025-01-13",
      "last_synced_at": "2026-11-19T08:57:37.125Z",
      "location_count": 28,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 21 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02014649"
    },
    {
      "nct_id": "NCT04459585",
      "title": "A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Healthy Subjects",
        "Drug-drug Interaction",
        "Pharmacokinetics",
        "Quizartinib"
      ],
      "interventions": [
        {
          "name": "Dabigatran Etexilate Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Quizartinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 20,
      "start_date": "2020-08-28",
      "completion_date": "2020-10-20",
      "has_results": true,
      "last_update_posted_date": "2021-07-09",
      "last_synced_at": "2026-11-19T08:57:37.125Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04459585"
    },
    {
      "nct_id": "NCT06119685",
      "title": "IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "NHL",
        "Multiple Myeloma",
        "Blood Cancer",
        "Refractory Non-Hodgkin Lymphoma",
        "Relapsed Non-Hodgkin Lymphoma",
        "Refractory Multiple Myeloma",
        "Relapsed Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "IDP-023",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab",
          "type": "DRUG"
        },
        {
          "name": "Interleukin-2",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "Isatuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indapta Therapeutics, INC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 128,
      "start_date": "2023-10-25",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-06-03",
      "last_synced_at": "2026-11-19T08:57:37.125Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Lake Mary, Florida • Atlanta, Georgia + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06119685"
    },
    {
      "nct_id": "NCT07529808",
      "title": "Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Gastric Cancer",
        "Gastric Adenocarcinoma",
        "Gastric (Stomach) Cancer",
        "Gastroesophageal Adenocarcinoma",
        "Gastroesophageal Cancer (GC)",
        "Gastroesophageal Junction (GEJ) Adenocarcinoma",
        "Gastroesophageal Junction (GEJ) Cancer",
        "Gastrointestinal Cancer Metastatic",
        "Gastrointestinal Adenocarcinoma",
        "Gastrointestinal Cancers",
        "Colorectal (Colon or Rectal) Cancer",
        "Pancreatic Cancer",
        "CDH17-positive Advanced Solid Tumors",
        "Advanced Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "BHB810",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BigHat Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 164,
      "start_date": "2026-07-16",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-11-19T08:57:37.125Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Santa Monica, California • Fairfax, Virginia",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07529808"
    },
    {
      "nct_id": "NCT02410525",
      "title": "A Study Testing A Radioactive Compound Given Through A Vein With And Without The Non-Radioactive Compound, Given By Mouth, To Characterize Tissue Distribution Using Positron Emission Tomography Scanning",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "[11C]PF-06427878",
          "type": "DRUG"
        },
        {
          "name": "PF-06427878 10 mg",
          "type": "DRUG"
        },
        {
          "name": "PF-06427878 600 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 8,
      "start_date": "2015-05",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2015-10-29",
      "last_synced_at": "2026-11-19T08:57:37.125Z",
      "location_count": 3,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02410525"
    },
    {
      "nct_id": "NCT07444268",
      "title": "How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Hematologic Malignancies"
      ],
      "interventions": [
        {
          "name": "DSP-5336",
          "type": "DRUG"
        },
        {
          "name": "[14C]-DSP-5336",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2026-03-26",
      "completion_date": "2026-09-04",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-11-19T08:57:37.125Z",
      "location_count": 2,
      "location_summary": "Chapel Hill, North Carolina • Houston, Texas",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07444268"
    },
    {
      "nct_id": "NCT05387668",
      "title": "Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "BGB-23339",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BeiGene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-02-17",
      "completion_date": "2022-10-17",
      "has_results": false,
      "last_update_posted_date": "2022-12-16",
      "last_synced_at": "2026-11-19T08:57:37.125Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05387668"
    },
    {
      "nct_id": "NCT00398697",
      "title": "Phase I Perifosine and Gemcitabine Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Perifosine",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AEterna Zentaris",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2004-08",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2014-02-13",
      "last_synced_at": "2026-11-19T08:57:37.125Z",
      "location_count": 1,
      "location_summary": "Johnson City, Tennessee",
      "locations": [
        {
          "city": "Johnson City",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00398697"
    }
  ]
}